# US 2025/0375435 A1 · Compounds for treating infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375435 A1
- Document ID: US20250375435A1
- Status: Published application
- Kind: A1
- Application number: 18/877,007
- Filed: 2023-06-21
- Published: 2025-12-11
- Earliest claimed: 2022-06-21
- Assignees: Ohio State Innovation Foundation
- Applicants: Ohio State Innovation Foundation
- Inventors: Brian AHMER; Venkat GOPALAN; Anice SABAG-DAIGLE; Erin BOULANGER; Jamison LAW; Sai Sravya Varali KOVVALI; Anindita SENGUPTA; Pankajavalli THIRUGNANASAMBANTHAM; Steffen LINDERT; Austin COOL
- Web page: https://patentgrep.com/patent/US20250375435A1

## CPC

- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/136: having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A61K 31/145: having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2) (isothiourea A61K31/155)
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/4406: only substituted in position 3, e.g. zimeldine (nicotinic acid A61K31/455)
- A61K 31/4433: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 31/04: Antibacterial agents
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 213/75: Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 307/52: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C07D 311/58: other than with oxygen or sulphur atoms in position 2 or 4
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 513/04: Ortho-condensed systems
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are compositions and methods for treating a Salmonella infection. Disclosed herein are compositions and methods for inhibiting FraB in Salmonella. Disclosed herein are methods of increasing 6-phospho-fructose-aspartate within Salmonella bacteria.

## Claims

### Claim at position 1

1-69. (canceled)

### Claim 70

A method for treating an infection in a subject in need thereof, comprising administering to the subject a compound having of Formula (1), Formula (2), Formula (3), or Formula (4):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is OR1a or N(R1a)2, wherein R1a is in each case independently selected from H, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
R2 is H or OH;
Z is Z1—X, wherein Z1 is null, NH, S, O, CH2, CH2O, OCH2, OCH2O, CH2NH, NHCH2, CH2S, SCH2, X is P(O)(ORp)2, SO2N(Rp)2, SO2Rp*, wherein Rp is in each case independently selected from H or C1-8alkyl, and Rp* is C1-8alkyl;
one of Y1 and Y2 is NH2, and the other is Y*—Ar, wherein Y* is null, NH, or O, and Ar is aryl or C1-8heteroaryl;
X4 is N or CR4;
X6 is N or CR6;
R3 is F, Cl, Br, I, NO2, CN, R3a*, OR3a*, SR3a*, N(R3a*)2, SO3R3a*, SO2R3a*, SO2N(R3a*)2, C(O)R3a*; C(O)OR3a*, OC(O)R3a*; C(O)N(R3a*)2, N(R3a*)C(O)R3a*, OC(O)N(R3a*)2, N(R3a*)C(O)N(R3a*)2, wherein R3a*is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of R3a may together form a ring;
R4 is F, Cl, Br, I, NO2, CN, R4a*, OR4a*, SR4a*, N(R4a*)2, SO4R4a*, SO2R4a*, SO2N(R4a*)2, C(O)R4a*; C(O)OR4a*, OC(O)R4a*; C(O)N(R4a*)2, N(R4a*)C(O)R4a*, OC(O)N(R4a*)2, N(R4a*)C(O)N(R4a*)2, wherein R4a*is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of R4a may together form a ring;
R5 is F, Cl, Br, I, NO2, CN, R5a*, OR5a*, SR5a*, N(R5a*)2, SO5R5a*, SO2R5a*, SO2N(R5a*)2, C(O)R5a*; C(O)OR5a*, OC(O)R5a*; C(O)N(R5a*)2, N(R5a*)C(O)R5a*, OC(O)N(R5a*)2, N(R5a*)C(O)N(R5a*)2, wherein R5a*is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of R5a may together form a ring;
R6 is F, Cl, Br, I, NO2, CN, R6a*, OR6a*, SR6a*, N(R6a*)2, SO6R6a*, SO2R6a*, SO2N(R6a*)2, C(O)R6a*; C(O)OR6a*, OC(O)R6a*; C(O)N(R6a*)2, N(R6a*)C(O)R6a*, OC(O)N(R6a*)2, N(R6a*)C(O)N(R6a*)2, wherein R6a*is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of R6a may together form a ring;
Ar1 is aryl or C1-8heteroaryl;
Ar2 is aryl or C1-8heteroaryl;
Ar is C6aryl C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; and
R5 is C(O)OR5* or C(O)N(R5*)2, preferably C(O)N(R5*)2, wherein R5* is independently selected from H, C1-8alkyl, and C3-8cycloalkyl.

### Claim 71 (depends on 70)

The method of claim 70, comprising administering the compound of Formula (1), wherein R1 is OC1-8alkyl and R2 is OH.

### Claim 72 (depends on 70)

The method of claim 70, comprising administering the compound of Formula (1), wherein Z1 is null, O, CH2, CH2O, OCH2, or OCH2O.

### Claim 73 (depends on 70)

The method of claim 70, comprising administering the compound of Formula (1), wherein X is P(O)(OH)2, SO2NH2, SO2CH3.

### Claim 74 (depends on 70)

The method of claim 70, comprising administering the compound of Formula (2), wherein Y2 is NH2, and X4 is C—R4, wherein R4 is F, Cl, Br, I, CN, R4a*, OR4a*, C(O)OR4a*, or C(O)N(R4a*)2.

### Claim 75 (depends on 70)

The method of claim 70, comprising administering the compound of Formula (2), wherein R5 is F, Cl, Br, I, R4a*, or OR4a*, wherein R4a is Hor C1-4alkyl.

### Claim 76 (depends on 70)

The method of claim 70, comprising administering the compound of Formula (2), wherein Y2 is NH2, and X4 is C—R4, wherein R4C(O)N(R4a*)2, and R4a is independently selected from H, C1-4alkyl, or C1-8heterocyclyl.

### Claim 77 (depends on 70)

The method of claim 70, comprising administering the compound of Formula (2), wherein Y2 is NH2, and X4 is C—R4, wherein R4C(O)N(R4a*)2, wherein both of R4a together form a ring.

### Claim 78 (depends on 70)

The method of claim 70, comprising administering the compound of Formula (3), wherein Ar1 is pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl, or Ar1 has the formula:
R7 is F, Cl, Br, I, NO2, CN, R7a*, OR7a*, SR7a*, N(R7a*)2, SO7R7a*, SO2R7a*, SO2N(R7a*)2, C(O)R7a*; C(O)OR7a*, OC(O)R7a*; C(O)N(R7a*)2, N(R7a*)C(O)R7a*, OC(O)N(R7a*)2, N(R7a*)C(O)N(R7a*)2, wherein R7a* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of R7a may together form a ring;
R8 is F, Cl, Br, I, NO2, CN, R8a*, OR8a*, SR8a*, N(R8a*)2, SO8R8a*, SO2R8a*, SO2N(R8a*)2, C(O)R8a*; C(O)OR8a*, OC(O)R8a*; C(O)N(R8a*)2, N(R8a*)C(O)R8a*, OC(O)N(R8a*)2, N(R8a*)C(O)N(R8a*)2, wherein R8a* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of R8a may together form a ring;
R9 is F, Cl, Br, I, NO2, CN, R9a*, OR9a*, SR9a*, N(R9a*)2, SO9R9a*, SO2R9a*, SO2N(R9a*)2, C(O)R9a*; C(O)OR9a*, OC(O)R9a*; C(O)N(R9a*)2, N(R9a*)C(O)R9a*, OC(O)N(R9a*)2, N(R9a*)C(O)N(R9a*)2, wherein R9a* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of R9a may together form a ring.

### Claim 79 (depends on 70)

The method of claim 70, comprising administering the compound of Formula (3), wherein Ar1 has the formula:
wherein 2 of R7, R8, and R9 are H, and the other is OH, CH2NH2, CH2OH, C1-6alkyl, F, Cl, Br, or I.

### Claim 80 (depends on 70)

The method of claim 70, comprising administering the compound of Formula (3), wherein Ar2 has the formula:
R10 is F, Cl, Br, I, NO2, CN, R10a*, OR10a*, SR10a*, N(R10a*)2, SO10R10a*, SO2R10a*, SO2N(R10a*)2, C(O)R10a*; C(O)OR10a*, OC(O)R10a*; C(O)N(R10a*)2, N(R10a*)C(O)R10a*, OC(O)N(R10a*)2, N(R10a*)C(O)N(R10a*)2, wherein R10a* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of R10a* may together form a ring;
R11 is F, CI, Br, I, NO2, CN, R11a*, OR11a*, SR11a*, N(R11a*)2, SO11R11a*, SO2R11a*, SO2N(R11a*)2, C(O)R11a*; C(O)OR11a*, OC(O)R11a*; C(O)N(R11a*)2, N(R11a*)C(O)R11a*, OC(O)N(R11a*)2, N(R11a*)C(O)N(R11a*)2, wherein R11a*is in each case independently selected from hydrogen, C1-11alkyl, aryl, C1-11heteroaryl, C3-11cycloalkyl, or C1-11heterocyclyl; wherein two or more of R11a may together form a ring;
R12 is F, Cl, Br, I, NO2, CN, R12a*, OR12a*, SR12a*, N(R12a*)2, SO12R12a*, SO2R12a*, SO2N(R12a*)2, C(O)R12a*; C(O)OR12a*, OC(O)R12a*; C(O)N(R12a*)2, N(R12a*)C(O)R12a*, OC(O)N(R12a*)2, N(R12a*)C(O)N(R12a*)2, wherein R12a*is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of R12a may together form a ring.

### Claim 81 (depends on 80)

The method of claim 80, wherein 2 of R10, R11, and R12 are H, and the other is OH, CH2NH2, CH2OH, C1-6alkyl, F, Cl, Br, or I.

### Claim 82 (depends on 70)

The method of claim 70, comprising administering the compound of Formula (4), having the formula:
wherein
R5a*is selected from H C1-8alkyl, and C3-8cycloalkyl;
Ry1 is selected from H, F, Cl, Br, C1-4alkyl, OH, OC1-4alkyl, NH2, NHC1-4alkyl, N(C1-4alkyl)2;
Ry2 is selected from H, F, Cl, Br, C1-4alkyl, OH, OC1-4alkyl, NH2, NHC1-4alkyl, N(C1-4alkyl)2;
Ry3 is selected from H, F, Cl, Br, C1-4alkyl, OH, OC1-4alkyl, NH2, NHC1-4alkyl, N(C1-4alkyl)2;
Ry4 is selected from H, F, Cl, Br, C1-4alkyl, OH, OC1-4alkyl, NH2, NHC1-4alkyl, N(C1-4alkyl)2;
Ry5 is selected from H, F, Cl, Br, C1-4alkyl, OH, OC1-4alkyl, NH2, NHC1-4alkyl, N(C1-4alkyl)2;
wherein any two of Ry1, Ry2, Ry3, Ry4, and Ry5 may together form a ring.

### Claim 83 (depends on 82)

The method of claim 82, wherein R5a*is methyl, ethyl, isopropyl, n-propyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, CH2cyclopropyl, CH2cyclobutyl, CH2cyclopentyl, CH2cyclohexyl, or CH2phenyl.

### Claim 84 (depends on 82)

The method of claim 82, wherein Ry2, Ry3, Ry4, and Ry5 are each H, and Ry1 is F, Cl, Br, C1-4alkyl, OH, OC1-4alkyl, NH2, NHC1-4alkyl, or N(C1-4alkyl)2.

### Claim 85 (depends on 70)

The method of claim 70, wherein the infection is a Salmonella infection.

### Claim 86 (depends on 85)

The method of claim 85, further comprising administering to the patient a Salmonella probiotic that is engineered to compete with Salmonella for nutrients other than F-Asn.

### Claim 87 (depends on 85)

The method of claim 85, further comprising administering to the patient an engineered Salmonella strain having at least the following mutations: DSPI1, DSPI2, DfraRBDAE4, and DasnB80::kan.

### Claim 88

A compound having the formula:
or pharmaceutically acceptable salt thereof, wherein
Z1 is selected from null, CH2, CH2CH2, O, NRn1, S, C(═O), OC(═O), NRn1(═O),
Ra is selected from C1-8alkyl, C3-8cycloalkyl, C6-12aryl, C2-12heterocyclyl, C1-12heteroaryl, wherein
Ra may be substituted one or more times by F, Cl, Br, I, C1-4alkyl, aryl, heteroaryl, OH, COOH, CN, NH2, NHC1-8alkyl, N(C1-8alkyl)2, or OC1-8alkyl,
wherein Ra and Rn1 may together form a ring; and
Z2 is selected from null, CH2, CH2CH2, O, NRn2, S, C(═O), OC(═O), NRn2(═O),
Rb is selected from C1-8alkyl, OC1-5alkyl, NHC1-8alkyl, N(C1-5alkyl)2, C3-8cycloalkyl, C6-12aryl, C2-12heterocyclyl, C1-12heteroaryl, wherein Rb may be substituted one or more times by F, Cl, Br, I, C1-4alkyl, aryl, heteroaryl, OH, COOH, CN, NH2, NHC1-8alkyl, N(C1-5alkyl)2, or OC1-8alkyl,
wherein Rb and Rn2 may together form a ring; or
a compound having the formula:
or a pharmaceutically acceptable salt thereof, wherein:
Rh is selected from F, Cl, Br, I, NO2, CN, Rh*, ORh*, SRh*, N(Rh*)2, SO3Rh*, SO2Rh*, SO2N(Rh*)2, C(O)Rh*, C(O)ORh*, OC(O)Rh*, C(O)N(Rh*)2, N(Rh*)C(O)Rh*, OC(O)N(Rh*)2, N(Rh*)C(O)N(Rh*)2, or N(Rh*)C(S)N(Rh*)2, wherein Rh* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of Rh* may together form a ring, wherein Rh* may be substituted one or more times by Rz4.
Ri is selected from F, Cl, Br, I, NO2, CN, Ri*, ORi*, SRi*, N(Ri*)2, SO3Ri*, SO2Ri*, SO2N(Ri)2, C(O)Ri*, C(O)ORi*, OC(O)Ri*, C(O)N(Ri*)2, N(Ri*)C(O)Ri*, OC(O)N(Ri*)2, N(Ri*)C(O)N(Ri*)2, or N(Ri*)C(S)N(Ri*)2, wherein Ri*is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of Ri* may together form a ring, wherein Ri* may be substituted one or more times by Rz4.
Ri is selected from F, Cl, Br, I, NO2, CN, Ri*, ORi*, SRi*, N(Ri*)2, SO3Ri*, SO2Ri*, SO2N(Ri*)2, C(O)Ri*, C(O)ORi*, OC(O)Ri*, C(O)N(Ri*)2, N(Ri*)C(O)Ri*, OC(O)N(Ri*)2, N(Ri*)C(O)N(Ri*)2, or N(Ri*)C(S)N(Ri*)2, wherein Ri* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of Ri* may together form a ring, wherein Ri* may be substituted one or more times by Rz4.
Rk is selected from F, Cl, Br, I, NO2, CN, Rk*, ORk*, SRk*, N(Rk*)2, SO3Rk*, SO2Rk*, SO2N(Rk*)2, C(O)Rk*, C(O)ORk*, OC(O)Rk*, C(O)N(Rk*)2, N(Rk*)C(O)Rk*, OC(O)N(Rk*)2, N(Rk*)C(O)N(Rk*)2, or N(Rk*)C(S)N(Rk*)2, wherein Rk* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of Rk* may together form a ring, wherein Rk* may be substituted one or more times by Rz4.
Rl is selected from F, Cl, Br, I, NO2, CN, Rl*, ORl*, SRl*, N(Rl*)2, SO3Rl*, SO2Rl*, SO2N(Rl*)2, C(O)Rl*, C(O)ORl*, OC(O)Rl*, C(O)N(Rl*)2, N(Rl*)C(O)Rl*, OC(O)N(Rl*)2, N(Rl*)C(O)N(Rl*)2, or N(Rl*)C(S)N(Rl*)2, wherein Rl* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of Rl* may together form a ring, wherein Rl* may be substituted one or more times by Rz4.
Rm is selected from F, Cl, Br, I, NO2, CN, Rm*, ORm*, SRm*, N(Rm*)2, SO3Rm*, SO2Rm*, SO2N(Rm*)2, C(O)Rm*, C(O)ORm*, OC(O)Rm*, C(O)N(Rm*)2, N(Rm*)C(O)Rm*, OC(O)N(Rm*)2, N(Rm*)C(O)N(Rm*)2, or N(Rm*)C(S)N(Rm*)2, wherein Rm* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of Rh* may together form a ring, wherein Rm* may be substituted one or more times by Rz4.
Rn is selected from F, Cl, Br, I, NO2, CN, Rn*, ORn*, SRn*, N(Rn*)2, SO3Rn*, SO2Rn*, SO2N(Rn*)2, C(O)Rn*, C(O)ORn*, OC(O)Rn*, C(O)N(Rn*)2, N(Rn*)C(O)Rn*, OC(O)N(Rn*)2, N(Rn*)C(O)N(Rn*)2, or N(Rn*)C(S)N(Rn*)2, wherein Rn* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of Rn* may together form a ring, wherein Rn* may be substituted one or more times by Rz4.
Ro is selected from F, Cl, Br, I, NO2, CN, Ro*, ORo*, SRo*, N(Ro*)2, SO3Ro*, SO2Ro*, SO2N(Ro*)2, C(O)Ro*, C(O)ORo*, OC(O)Ro*, C(O)N(Ro*)2, N(Ro*)C(O)Ro*, OC(O)N(Ro*)2, N(Ro*)C(O)N(Ro*)2, or N(Ro*)C(S)N(Ro*)2, wherein Ro* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of Ro* may together form a ring, wherein Ro* may be substituted one or more times by Rz4.
Rp is selected from F, Cl, Br, I, NO2, CN, Rp*, ORp*, SRp*, N(Rp*)2, SO3Rp*, SO2Rp*, SO2N(Rp*)2, C(O)Rp*, C(O)ORp*, OC(O)Rp*, C(O)N(Rp*)2, N(Rp*)C(O)Rp*, OC(O)N(Rp*)2, N(RP*)C(O)N(Rp*)2, or N(Rp*)C(S)N(Rp*)2, wherein Rp* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of Rp* may together form a ring, wherein Rp* may be substituted one or more times by Rz4.
Rq is selected from F, Cl, Br, I, NO2, CN, Rq*, ORq*, SRq*, N(Rq*)2, SO3Rq*, SO2Rq*, SO2N(Rq*)2, C(O)Rq*, C(O)ORq*, OC(O)Rq*, C(O)N(Rq*)2, N(Rq*)C(O)Rq*, OC(O)N(Rq*)2, N(Rq*)C(O)N(Rq*)2, or N(Rq*)C(S)N(Rq*)2, wherein Rq* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of Rq* may together form a ring, wherein Rq* may be substituted one or more times by Rz4; and
Rz4 is in each case independently selected from F, Cl, Br, I, C1-4alkyl, aryl, heteroaryl, OH, OC1-4alkyl, NH2, NHC1-4alkyl, or N(C1-4alkyl)2; or
a compound having the formula:
or pharmaceutically acceptable salt thereof, wherein
Ar is C6aryl C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; and
R5 is C(O)OR5* or C(O)N(R5*)2, preferably C(O)N(R5*)2, wherein R5* is independently selected from H, C1-8alkyl, and C3-8cycloalkyl; or
a compound having the formula:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is OR1a or N(R1a)2, wherein R1a is in each case independently selected from H, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
R2 is H or OH;
Z is Z1—X, wherein Z1 is null, NH, S, O, CH2, CH2O, OCH2, OCH2O, CH2NH, NHCH2, CH2S, SCH2, X is P(O)(ORp)2, SO2N(Rp)2, SO2Rp*, wherein Rp is in each case independently selected from H or C1-8alkyl, and Rp* is C1-8alkyl; or
a compound having the formula:
one of Y1 and Y2 is NH2, and the other is Y*—Ar, wherein Y* is null, NH, or O, and Ar is aryl or C1-8heteroaryl;
X4 is N or CR4;
X6 is N or CR6;
R3 is is F, Cl, Br, I, NO2, CN, R3a*, OR3a*, SR3a*, N(R3a*)2, SO3R3a*, SO2R3a*, SO2N(R3a*)2, C(O)R3a*; C(O)OR3a*, OC(O)R3a*; C(O)N(R3a*)2, N(R3a*)C(O)R3a*, OC(O)N(R3a*)2, N(R3a*)C(O)N(R3a*)2, wherein R3a* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of R3a* may together form a ring;
R4 is is F, Cl, Br, I, NO2, CN, R4a*, OR4a*, SR4a*, N(R4a*)2, SO4R4a*, SO2R4a*, SO2N(R4a*)2, C(O)R4a*; C(O)OR4a*, OC(O)R4a*; C(O)N(R4a*)2, N(R4a*)C(O)R4a*, OC(O)N(R4a*)2, N(R4a*)C(O)N(R4a*)2, wherein R4a* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of R4a* may together form a ring;
R5 is is F, Cl, Br, I, NO2, CN, R5a*, OR5a*, SR5a*, N(R5a*)2, SO5R5a*, SO2R5a*, SO2N(R5a*)2, C(O)R5a*; C(O)OR5a*, OC(O)R5a*; C(O)N(R5a*)2, N(R5a*)C(O)R5a*, OC(O)N(R5a*)2, N(R5a*)C(O)N(R5a*)2, wherein R5a* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of R5a* may together form a ring;
R6 is is F, Cl, Br, I, NO2, CN, R6a*, OR6a*, SR6a*, N(R6a*)2, SO6R6a*, SO2R6a*, SO2N(R6a*)2, C(O)R6a*; C(O)OR6a*, OC(O)R6a*; C(O)N(R6a*)2, N(R6a*)C(O)R6a*, OC(O)N(R6a*)2, N(R6a*)C(O)N(R6a*)2, wherein R6a* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl; wherein two or more of R6a* may together form a ring;
Ar1 is aryl or C1-8heteroaryl; and
Ar2 is aryl or C1-8heteroaryl.

### Claim 89

An engineered Salmonella strain having at least the following mutations: DSPI1, DSPI2, DfraRBDAE4, and DasnB80::kan.
